Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 23:02 | 2026-02-13 | CING | Cingulate Inc. | Hargroves Thomas Jeffrey | Director | Pharmaceutical Preparations | BUY | $5.04 | 97,276 | $490,271 | 97,468 | +50,664.6% |
| 2026-06-08 22:07 | 2026-06-04 | NBIX | NEUROCRINE BIOSCIENCES INC | Norwalk Leslie V | Director | Biological Products, (No Diagnostic Substances) | SALE | $168.06 | 1,250 | $210,072 | 2,838 | -30.6% |
| 2026-06-08 22:10 | 2026-06-08 | USNA | USANA HEALTH SCIENCES INC | Jones Paul A. | Officer; CHIEF PEOPLE OFFICER | Medicinal Chemicals & Botanical Products | SALE | $18.50 | 5,561 | $102,879 | 0 | -100.0% |
| 2026-06-08 22:13 | 2026-06-04 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | Pharmaceutical Preparations | SALE | $0.41 | 105,565 | $43,028 | 377,211 | -21.9% |
| 2026-06-08 22:19 | 2026-06-05 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | Pharmaceutical Preparations | SALE | $0.06 | 735,462 | $45,599 | 0 | -100.0% |
| 2026-06-08 22:19 | 2026-06-04 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | Pharmaceutical Preparations | BUY | $0.08 | 843,622 | $64,115 | 505,302 | +100.0% |
| 2026-06-08 22:01 | 2026-06-04 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $67.67 | 80,000 | $5,413,288 | 4,318,447 | -1.8% |
| 2026-06-08 20:37 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Director | Pharmaceutical Preparations | SALE | $10.73 | 2,625 | $28,166 | 9,767 | -21.2% |
| 2026-06-08 20:41 | 2026-06-04 | LQDA | Liquidia Corp | Manning Paul B | Director | Pharmaceutical Preparations | SALE | $63.91 | 200,000 | $12,782,060 | 798,335 | -20.0% |
| 2026-06-08 20:30 | 2026-06-04 | LQDA | Liquidia Corp | Bloch Stephen M | Director | Pharmaceutical Preparations | SALE | $64.95 | 84,800 | $5,507,785 | 1,785,242 | -4.5% |
| 2026-06-08 20:33 | 2026-06-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $547.62 | 9,500 | $5,202,437 | 40,513 | -19.0% |
| 2026-06-08 20:34 | 2026-06-04 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $50.00 | 3,471 | $173,550 | 67,468 | -4.9% |
| 2026-06-08 20:01 | 2026-06-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D | Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $34.35 | 6,153 | $211,356 | 1,177,529 | -0.5% |
| 2026-06-08 20:01 | 2026-06-04 | GYRE | GYRE THERAPEUTICS, INC. | Ye Weiguo | Officer; Chief Operating Officer | Pharmaceutical Preparations | OPT+S | $6.25 | 34,976 | $218,562 | 700,000 | -4.8% |
| 2026-06-08 18:53 | 2026-06-04 | PHVS | Pharvaris N.V. | Nijdam Anna | Officer; Principal Accounting Officer | Pharmaceutical Preparations | SALE | $30.87 | 2,670 | $82,425 | 46,275 | -5.5% |
| 2026-06-05 20:10 | 2026-06-03 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | Pharmaceutical Preparations | BUY | $17.48 | 2,500 | $43,700 | 22,500 | +12.5% |
| 2026-06-05 20:05 | 2026-06-03 | LFVN | Lifevantage Corp | BEINDORFF MICHAEL A | Director | Pharmaceutical Preparations | SALE | $8.55 | 10,000 | $85,459 | 41,625 | -19.4% |
| 2026-06-05 20:30 | 2026-06-04 | CGON | CG Oncology, Inc. | POST LEONARD E | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $54.50 | 1,000 | $54,500 | 0 | -100.0% |
| 2026-06-05 20:14 | 2026-06-03 | INSM | INSMED Inc | Smith Michael Alexander | Officer; Chief Legal Officer | Pharmaceutical Preparations | SALE | $102.27 | 2,159 | $220,801 | 39,454 | -5.2% |
| 2026-06-05 20:11 | 2026-06-03 | INSM | INSMED Inc | Flammer Martina M.D. | Officer; Chief Medical Officer | Pharmaceutical Preparations | SALE | $102.90 | 4,424 | $455,248 | 60,486 | -6.8% |
| 2026-06-05 20:14 | 2026-06-03 | INSM | INSMED Inc | Bonstein Sara | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $102.27 | 2,404 | $245,857 | 69,082 | -3.4% |
| 2026-06-05 20:12 | 2026-06-03 | INSM | INSMED Inc | Lewis William | Director, Officer; Chair and CEO | Pharmaceutical Preparations | SALE | $102.27 | 7,605 | $777,763 | 265,432 | -2.8% |
| 2026-06-05 20:10 | 2026-06-03 | AIMD | Ainos, Inc. | chiang yao-chung | Director | Pharmaceutical Preparations | BUY | $2.13 | 2,000 | $4,260 | 7,779 | +34.6% |
| 2026-06-06 00:00 | 2026-06-03 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $78.71 | 5,500 | $432,905 | 205,648 | -2.6% |
| 2026-06-05 22:38 | 2026-06-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Director, Officer, 10% owner; President and CEO | Biological Products, (No Diagnostic Substances) | SALE | $308.12 | 25,000 | $7,702,985 | 1,450,253 | -1.7% |
| 2026-06-05 22:40 | 2026-06-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Director, Officer, 10% owner; President, R&D | Biological Products, (No Diagnostic Substances) | SALE | $308.11 | 25,000 | $7,702,825 | 1,378,155 | -1.8% |
| 2026-06-05 22:29 | 2026-06-03 | XERS | Xeris Biopharma Holdings, Inc. | PERSKY MARLA | Director | Pharmaceutical Preparations | SALE | $5.90 | 15,500 | $91,433 | 126,500 | -10.9% |
| 2026-06-05 22:17 | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | JOHNSON JOHN | Director | Pharmaceutical Preparations | SALE | $6.09 | 15,000 | $91,422 | 683,083 | -2.1% |
| 2026-06-05 22:18 | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Pharmaceutical Preparations | SALE | $6.09 | 16,000 | $97,507 | 126,500 | -11.2% |
| 2026-06-05 22:18 | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | HALKUFF DAWN | Director | Pharmaceutical Preparations | SALE | $6.09 | 20,000 | $121,886 | 95,000 | -17.4% |
| 2026-06-05 21:56 | 2026-06-04 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $34.10 | 30,000 | $1,023,009 | 211,930 | -12.4% |
| 2026-06-05 21:57 | 2026-06-04 | PCRX | Pacira BioSciences, Inc. | WILLIAMS KRISTEN | Officer; Chief Administrative Officer | Pharmaceutical Preparations | SALE | $22.27 | 10,259 | $228,468 | 167,062 | -5.8% |
| 2026-06-05 22:04 | 2026-06-04 | INKT | MiNK Therapeutics, Inc. | Ryan Barbara | Director | Biological Products, (No Diagnostic Substances) | SALE | $12.76 | 1,500 | $19,141 | 21,969 | -6.4% |
| 2026-06-05 21:26 | 2026-06-03 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner; CEO and Chairman | Pharmaceutical Preparations | SALE | $4.37 | 8,285 | $36,209 | 173,224 | -4.6% |
| 2026-06-05 21:29 | 2026-06-04 | IBRX | ImmunityBio, Inc. | Simon Barry J. | Director | Biological Products, (No Diagnostic Substances) | SALE | $7.18 | 23,033 | $165,306 | 2,827,788 | -0.8% |
| 2026-06-05 21:02 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Director, Officer; CEO and President | Biological Products, (No Diagnostic Substances) | SALE | $3.58 | 23,588 | $84,459 | 2,175,796 | -1.1% |
| 2026-06-05 21:03 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | Biological Products, (No Diagnostic Substances) | SALE | $3.62 | 40,000 | $144,800 | 883,735 | -4.3% |
| 2026-06-05 20:42 | 2026-06-04 | EQ | Equillium, Inc. | Connelly Stephen | Officer; President and CSO | Pharmaceutical Preparations | SALE | $3.13 | 230,975 | $723,829 | 762,025 | -23.3% |
| 2026-06-05 20:42 | 2026-06-05 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer; Sr. Vice President and COO | Pharmaceutical Preparations | OPT+S | $2.93 | 14,584 | $42,737 | 62,586 | -18.9% |
| 2026-06-05 20:43 | 2026-06-03 | QURE | uniQure N.V. | Kaye Jack | Director | Pharmaceutical Preparations | OPT+S | $30.01 | 2,645 | $79,376 | 20,439 | -11.5% |
| 2026-06-05 20:31 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $546.33 | 9,500 | $5,190,127 | 40,513 | -19.0% |
| 2026-06-05 20:31 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Pharmaceutical Preparations | OPT+S | $546.28 | 10,000 | $5,462,824 | 18,876 | -34.6% |
| 2026-06-05 20:32 | 2026-06-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | Officer; EVP, CHIEF SCIENTIFIC OFFICER | Biological Products, (No Diagnostic Substances) | SALE | $2.70 | 731 | $1,975 | 67,297 | -1.1% |
| 2026-06-05 20:33 | 2026-06-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | Director, Officer; CEO | Biological Products, (No Diagnostic Substances) | SALE | $2.70 | 15,380 | $41,543 | 248,313 | -5.8% |
| 2026-06-05 20:33 | 2026-06-03 | EDIT | Editas Medicine, Inc. | Parison Amy | Officer; SVP, Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $2.70 | 464 | $1,253 | 14,970 | -3.0% |
| 2026-06-05 20:15 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Seth Alpna | Director | Pharmaceutical Preparations | SALE | $10.72 | 2,625 | $28,140 | 9,767 | -21.2% |
| 2026-06-05 20:15 | 2026-06-03 | INSM | INSMED Inc | Adsett Roger | Officer; Chief Operating Officer | Pharmaceutical Preparations | SALE | $102.27 | 2,370 | $242,380 | 98,603 | -2.3% |
| 2026-06-05 20:19 | 2026-06-03 | ALDX | Aldeyra Therapeutics, Inc. | Brady Todd C | Director, Officer; President and CEO | Pharmaceutical Preparations | BUY | $1.67 | 250,000 | $418,450 | 1,721,298 | +17.0% |
| 2026-06-05 20:01 | 2026-06-03 | OCUL | OCULAR THERAPEUTIX, INC | Waheed Nadia | Officer; Chief Medical Officer | Pharmaceutical Preparations | SALE | $8.27 | 14,828 | $122,628 | 300,079 | -4.7% |
| 2026-06-05 17:46 | 2026-06-04 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | Pharmaceutical Preparations | BUY | $9.31 | 50,000 | $465,295 | 936,000 | +5.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.